Just noticed something interesting - Knoll Capital dropped $5.37 million into SSR Mining back in February, grabbing 245k shares at $25.91. That's a pretty bold move for a fund that's mostly biotech plays. SSR's been absolutely crushing it though, up 180% in the past year while the S&P barely moved 16%. The company's actually profitable too - pulled in $1.6B revenue last year and generated nearly $472M in operating cash flow. What caught my eye is they're positioning SSR as a hedge against their biotech concentration. Makes sense - when you're heavy on clinical-stage drug developers, adding a real precious metals producer with actual production and cash flow is solid portfolio construction. SSR operates mines across Turkey, US, Canada, Argentina, so there's geographic diversification too. That said, the stock's already had a massive run. Mining cycles are real, and after moves like this, you gotta wonder if the macro backdrop can keep cooperating. Gold's been strong but nothing's guaranteed. Still, interesting signal from an institutional player.